Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the basis of...

Descripción completa

Detalles Bibliográficos
Autores principales: Troya, Jesús, Dueñas, Carlos, Irazola, Idoia, de los Santos, Ignacio, de la Fuente, Sara, Gil, Desiré, Hernández, Cristina, Galindo, María José, Gómez, Julia, Delgado, Elisabeth, Moreno-García, Estela, Posada, Guillermo, Aldámiz, Teresa, Iribarren, Jose Antonio, Guerra, José Manuel, Morán, Miguel Ángel, Galera, Carlos, Fuente, Javier, Peláez, Ana, Cervero, Miguel, Garcinuño, María, Montero, Marta, Ceballos, Francisco, Buzón, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
4850
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276328/
https://www.ncbi.nlm.nih.gov/pubmed/35713430
http://dx.doi.org/10.1097/MD.0000000000029252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276328/
https://www.ncbi.nlm.nih.gov/pubmed/35713430
http://dx.doi.org/10.1097/MD.0000000000029252

Ejemplares similares